# EDGAR Filing Document

**Accession Number:** 0001422142
**File Stem:** 0001193125-23-083652
**Filing Date:** 2023-3
**Character Count:** 18130
**Document Hash:** 03b0d0681dfe3e7cb43f1e4d162ae25b
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-23-083652.hdr.sgml**: 20230329

**ACCESSION NUMBER**: 0001193125-23-083652

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 6

**FILED AS OF DATE**: 20230329

**DATE AS OF CHANGE**: 20230329

**EFFECTIVENESS DATE**: 20230329

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Aadi Bioscience, Inc.
- **CENTRAL INDEX KEY:** 0001422142
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 611547850
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-270933
- **FILM NUMBER:** 23775252

**BUSINESS ADDRESS:**
- **STREET 1:** 17383 SUNSET AVENUE
- **STREET 2:** SUITE A250
- **CITY:** PACIFIC PALISADES
- **STATE:** CA
- **ZIP:** 90272
- **BUSINESS PHONE:** 424-473-8055

**MAIL ADDRESS:**
- **STREET 1:** 17383 SUNSET AVENUE
- **STREET 2:** SUITE A250
- **CITY:** PACIFIC PALISADES
- **STATE:** CA
- **ZIP:** 90272

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Aerpio Pharmaceuticals, Inc.
- **DATE OF NAME CHANGE:** 20170316

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ZETA ACQUISITION CORP II
- **DATE OF NAME CHANGE:** 20071227

**As filed with the Securities and Exchange Commission on March 29, 2023** 

**Registration No. 333-** 

------

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

------

**FORM S-8** 

**REGISTRATION STATEMENT** 

***Under***

***The Securities Act of 1933***

------

## AADI BIOSCIENCE, INC.
**(Exact name of Registrant as specified in its charter)** 

------

---

| | |
|:---|:---|
| **Delaware** | **61-1547850** |
| **(State or other jurisdiction of**<br> **incorporation or organization)** | **(I.R.S. Employer**<br> **Identification No.)** |

---

**17383 Sunset Boulevard, Suite A250** 

**Pacific Palisades, California 90272** 

**(Address of Principal Executive Offices, including zip code)** 

**2021 Equity Incentive Plan** 

**2021 Employee Stock Purchase Plan** 

**(Full title of the plan)** 

**Scott Giacobello** 

**Interim Chief Executive Officer and President, and Chief Financial Officer** 

**17383 Sunset Boulevard, Suite A250** 

**Pacific Palisades, California 90272** 

**(424) 473-8055** 

**(Name, address and telephone number, including area code, of agent for service)** 

------

***Copies to:***

**Dan Koeppen, Esq.** 

**Robert L. Wernli, Jr., Esq.** 

**Savir S. Punia, Esq.** 

**Wilson Sonsini Goodrich & Rosati, P.C.** 

**12235 El Camino Real** 

**San Diego, California 92130** 

------

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
|  |  | Emerging growth company | ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

------

**REGISTRATION OF ADDITIONAL SECURITIES** 

**PURSUANT TO GENERAL INSTRUCTION E** 

This Registration Statement on Form S-8 (the "Registration Statement") is filed by Aadi Bioscience, Inc. (the "Registrant") for the purpose of registering (i) 977,400 additional shares of common stock of the Registrant that may be issued pursuant to the Aadi Bioscience, Inc. 2021 Equity Incentive Plan, commencing January 1, 2023, and (ii) 244,350 additional shares of common stock of the Registrant that may be issued pursuant to the Aadi Bioscience, Inc. 2021 Employee Stock Purchase Plan, commencing January 1, 2023.

In accordance with General Instruction E to Form S-8, the contents of the previous Registration Statements on Form S-8 (File Nos. 333-259787 and 333-263639) filed by the Registrant with the Securities and Exchange Commission (the "SEC") on September 24, 2021 and March 17, 2022, respectively, in each case are incorporated by reference into this Registration Statement, except as modified or superseded hereby.

**PART II** 

**INFORMATION REQUIRED IN REGISTRATION STATEMENT** 

---

| | |
|:---|:---|
| **Item 3. Incorporation** | **of Documents by Reference.**  |

---

The Registrant hereby incorporates by reference into this Registration Statement the following documents previously filed with the SEC:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) The Registrant's Annual Report on [Form 10-K](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1422142/000162828023009583/aadi-20221231.htm) for the fiscal year ended December 31, 2022, filed with the SEC on March 29, 2023 (the "Annual Report").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) All other reports filed pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as
amended (the "Exchange Act"), since the end of the fiscal year covered by the Annual Report (other than the portions of these documents not deemed to be filed).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3) The description of the Registrant's Common Stock contained in the Company's Annual Report on [Form 10-K](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1422142/000162828023009583/aadi-20221231.htm) filed with the SEC on March 29, 2023, including any amendment or report filed for the purpose of updating such description.

All documents filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement that indicates that all securities offered have been sold or that deregisters all securities then remaining unsold shall be deemed to be incorporated by reference in this Registration Statement and to be part hereof from the date of filing of such documents; *provided*, *however*, that documents or information deemed to have been furnished and not filed in accordance with the rules of the SEC shall not be deemed incorporated by reference into this Registration Statement. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document which also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

**Item 8. Exhibits.**

The Registrant has filed the exhibits listed on the accompanying Exhibit Index of this Registration Statement.

------

**EXHIBIT INDEX** 

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Exhibit** |  | **Filed<br>Herewith** | **Incorporated by Reference** | **Incorporated by Reference** | **Incorporated by Reference** | **Incorporated by Reference** |
| **Number** | **Exhibit Description** | **Filed<br>Herewith** | **Form** | **File No.** | **Exhibit** | **Filing Date** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.3 | [Aadi Bioscience, Inc. 2021 Equity Incentive Plan.](http://www.sec.gov/Archives/edgar/data/1422142/000119312521257910/d119681dex106.htm) |  | 8-K | 001-38560 | 10.6 | August 27, 2021 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.4 | [Form of Stock Option Agreement under the Aadi Bioscience, Inc. 2021 Equity Incentive Plan.](http://www.sec.gov/Archives/edgar/data/1422142/000119312521257910/d119681dex107.htm) |  | 8-K | 001-38560 | 10.7 | August 27, 2021 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.5 | [Aadi Bioscience, Inc. 2021 Employee Stock Purchase Plan](http://www.sec.gov/Archives/edgar/data/1422142/000119312521257910/d119681dex108.htm) |  | 8-K | 001-38560 | 10.8 | August 27, 2021 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.1 | [Opinion of Wilson Sonsini Goodrich & Rosati, P.C.](d464068dex51.htm) | X |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;23.1 | [Consent of Independent Registered Public Accounting Firm, BDO USA, LLP.](d464068dex231.htm) | X |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;23.3 | [Consent of Wilson Sonsini Goodrich & Rosati, P.C. (included in Exhibit 5.1 hereto).](d464068dex51.htm) | X |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;24.1 | [Power of Attorney (included on the signature page hereto)](#sig) | X |  |  |  |  |
| 107.1 | [Filing Fee Table](d464068dexfilingfees.htm) | X |  |  |  |  |

---

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Los Angeles, State of California, on March 29, 2023.

---

| | |
|:---|:---|
| **AADI BIOSCIENCE, INC.** | **AADI BIOSCIENCE, INC.** |
|  By: | /s/ Scott Giacobello |
|  | Scott Giacobello |
|  | Interim Chief Executive Officer and President, and Chief Financial Officer |

---

**POWER OF ATTORNEY** 

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Neil Desai, Ph.D. and Scott Giacobello, and each of them, as his or her true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for such person in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments) on Form S-8, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact, proxy, and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that any said attorney-in-fact, proxy and agent, or any substitute of any of them, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated:

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| /s/ Scott Giacobello<br> Scott Giacobello | Interim Chief Executive Officer and President, and Chief Financial Officer<br>(Principal Executive Officer and Principal Financial and Accounting Officer) | March 29, 2023 |
| /s/ Caley Castelein<br> Caley Castelein | Chair of the Board of Directors | March 29, 2023 |
| /s/ Neil Desai<br> Neil Desai, Ph.D. | Director | March 29, 2023 |
| /s/ Anupam Dalal<br> Anupam Dalal, M.D. | Director | March 29, 2023 |
| /s/ Karin Hehenberger<br> Karin Hehenberger, M.D., Ph.D. | Director | March 29, 2023 |
| /s/ Behzad Aghazadeh<br> Behzad Aghazadeh, Ph.D. | Director | March 29, 2023 |
| /s/ Richard Maroun<br> Richard Maroun | Director | March 29, 2023 |
| /s/ Emma Reeve<br> Emma Reeve | Director | March 29, 2023 |

---

## Exhibit 5.1

**Exhibit 5.1** 

---

| | |
|:---|:---|
| ![LOGO](g464068g0327124245514.jpg) | Wilson Sonsini Goodrich & Rosati<br> Professional Corporation<br>650 Page Mill Road<br> Palo Alto, California 94304-1050<br>O: 650.493.9300<br> F: 650.493.6811 |

---

March 29, 2023

Aadi Bioscience, Inc.

17383 Sunset Boulevard, Suite A250

Pacific Palisades, California 90272

**Re: <u>Registration Statement on Form S-8</u>** 

Ladies and Gentlemen:

We have examined the Registration Statement on Form S-8 (the "<u>Registration Statement</u>") to be filed by Aadi Bioscience, Inc., a Delaware corporation (the "<u>Company</u>"), with the Securities and Exchange Commission on or about the date hereof, in connection with the registration under the Securities Act of 1933, as amended, of an aggregate of 1,221,750 shares (the "<u>Shares</u>") of the Company's common stock, par value $0.0001 per share ("<u>Common Stock</u>"), consisting of (i) 977,400 shares of Common Stock reserved for future issuance under the Company's 2021 Equity Incentive Plan (the "<u>2021 Plan</u>"), and (ii) 244,350 shares of Common Stock reserved for issuance under the Company's 2021 Employee Stock Purchase Plan. As the Company's legal counsel, we have reviewed the actions proposed to be taken by the Company in connection with the issuance and sale of the Shares to be issued under such plans (which plans are referred to herein as the "<u>Plans</u>").

It is our opinion that the Shares, when issued and sold in the manner referred to in the Plans and pursuant to the agreements that accompany the Plans, will be legally and validly issued, fully paid and nonassessable.

We consent to the use of this opinion as an exhibit to the Registration Statement, and further consent to the use of our name wherever appearing in the Registration Statement and any amendments thereto.

---

| |
|:---|
| Very truly yours, |
| /s/ Wilson Sonsini Goodrich & Rosati, P.C. |
| WILSON SONSINI GOODRICH & ROSATI, |
| Professional Corporation |

---

AUSTIN BEIJING BOSTON BRUSSELS HONG KONG LONDON LOS ANGELES NEW YORK PALO ALTO

SAN DIEGO SAN FRANCISCO SEATTLE SHANGHAI WASHINGTON, DC WILMINGTON, DE

## Exhibit 23.1

**Exhibit 23.1**![LOGO](g464068g17f84.jpg)

<u>Consent of Independent Registered Public Accounting Firm</u> 

Aadi Bioscience, Inc.

Pacific Palisades, California

We hereby consent to the incorporation by reference in this Registration Statement of our report dated March 28, 2023, relating to the consolidated financial statements of Aadi Bioscience, Inc. (the "Company") appearing in the Company's Annual Report on Form 10-K for the year ended December 31, 2022.

/s/ BDO USA, LLP

San Diego, California

March 29, 2023

## Ex-Filing

**Exhibit 107** 

**Calculation of Filing Fee Tables** 

**Form S-8** 

(Form Type)

**Aadi Bioscience, Inc.** 

(Exact name of registrant as specified in its charter)

**Table 1 – Newly Registered Securities** 

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| &nbsp;&nbsp;&nbsp;Security<br>Type | Security Class Title | Fee Calculation Rule | Amount<br>Registered<sup>(1)</sup> | Maximum<br>Aggregate<br>Offering Price | Fee Rate | Amount of<br>Registration<br>Fee |
| &nbsp;&nbsp;&nbsp;Equity | Common Stock, par value $0.0001 per share, reserved for issuance under the Registrant's 2021 Equity Incentive Plan | Rule 457(c) and Rule 457(h) | 977400<sup>(2)</sup>$7.19<sup>(4)</sup> | $7027506 | 0.0001102 | $775.00 |
| &nbsp;&nbsp;&nbsp;Equity | Common Stock, par value $0.0001 per share, reserved for issuance under the Registrant's 2021 Employee Stock Purchase Plan | Rule 457(c) and Rule 457(h) | 244350<sup>(3)</sup>$6.11<sup>(5)</sup> | $1493468 | 0.0001102 | $165.00 |
| &nbsp;&nbsp;&nbsp;Total Offering Amounts | &nbsp;&nbsp;&nbsp;Total Offering Amounts | &nbsp;&nbsp;&nbsp;Total Offering Amounts | 1221750 | $8520974 |  | $940.00 |
| &nbsp;&nbsp;&nbsp;Total Fee Offsets<sup>(6)</sup> | &nbsp;&nbsp;&nbsp;Total Fee Offsets<sup>(6)</sup> | &nbsp;&nbsp;&nbsp;Total Fee Offsets<sup>(6)</sup> |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net Fee Due | &nbsp;&nbsp;&nbsp;Net Fee Due | &nbsp;&nbsp;&nbsp;Net Fee Due |  |  |  | $940.00 |

---

(1) Pursuant to Rule 416(a) of the Securities Act of 1933, as amended (the "Securities Act"), this
registration statement (the "Registration Statement") shall also cover any additional shares of the Registrant's Common Stock that become issuable under the Registrant's 2021 Equity Incentive Plan (the "2021 Plan") or
the Registrant's 2021 Employee Stock Purchase Plan (the "2021 ESPP") by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without receipt of consideration or conversion of the
Registrant's Common Stock that increases the number of outstanding shares of Common Stock.

(2) Represents an automatic increase in the number of shares of Common Stock reserved for issuance pursuant to
future awards under the 2021 Plan as a result of the annual evergreen increase under the 2021 Plan.

(3) Represents an automatic increase in the number of shares of Common Stock reserved for issuance pursuant to
future awards under the 2021 ESPP as a result of the annual evergreen increase under the 2021 ESPP.

(4) Pursuant to Rule 457(c) and 457(h) under the Securities Act, and solely for the purpose of calculating the
registration fee, the proposed maximum offering price per share is $7.19, which is the average of the high and low prices of shares of Common Stock on The Nasdaq Capital Market ("Nasdaq") on March 24, 2023 (such date being within five
business days of the date that this Registration Statement was filed with the U.S. Securities and Exchange Commission (the "SEC")).

------

(5) Pursuant to Rule 457(c) and 457(h) under the Securities Act, and solely for the purpose of calculating the
registration fee, the proposed maximum offering price per share is $6.11, which is 85% of the average of the high and low prices of shares of Common Stock on Nasdaq on March 24, 2023 (such date being within five business days of the date that this
Registration Statement was filed with the SEC). Pursuant to the 2021 ESPP, the purchase price of the shares of common stock reserved for issuance thereunder will be 85% of the lower of the fair market value of the common stock on (i) the first
trading day of the offering period or (ii) the exercise date.

(6) The Registrant does not have any fee offsets.